Monalizumab
- CAS No.
- 1228763-95-8
- Chemical Name:
- Monalizumab
- Synonyms
- Monalizumab;Monalizumab (anti-NKG2A);Research Grade Monalizumab;Research Grade Monalizumab(DHD71901)
- CBNumber:
- CB58080948
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | Store at -20°C |
|---|---|
| form | Liquid |
| color | Colorless to light yellow |
| Water Solubility | Soluble in water |
| FDA UNII | 3ZXZ2V0588 |
| NCI Drug Dictionary | monalizumab |
Monalizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0437477 | Monalizumab 99.69% | 1228763-95-8 | 1mg | $320 | 2026-06-04 | Buy |
| ChemScene | CS-0437477 | Monalizumab 99.69% | 1228763-95-8 | 5mg | $1051 | 2026-06-04 | Buy |
| ChemScene | CS-0437477 | Monalizumab 99.69% | 1228763-95-8 | 10mg | $1679 | 2026-06-04 | Buy |
| ChemScene | CS-0437477 | Monalizumab 99.69% | 1228763-95-8 | 25mg | $3196 | 2026-06-04 | Buy |
| aablocks | AA027JBU | Monalizumab | 1228763-95-8 | 1mg | $215 | 2026-06-02 | Buy |
Monalizumab Chemical Properties,Uses,Production
Uses
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
Mechanism of action
Monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response.
in vivo
Monalizumab (50 μg, intratumoral injections, together with 8millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].
| Animal Model: | immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4] |
| Dosage: | 50μg, together with 8millions of activated NK cells |
| Administration: | intratumoral injections |
| Result: | Shows a synergestic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells. |
Monalizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Monalizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Beijing Solarbio Science & Tecnology Co., Ltd. | 17801761073 18101056239 | 3193328036@qq.com | China | 28150 | 68 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
